There are limited data examining the impact of radiotherapy (RT) on the efficacy of checkpoint inhibitors in patients with metastatic non–small-cell lung cancer (NSCLC). In this study, we aimed to evaluate the impact of RT on the efficacy and toxicity of anti-programmed death 1 treatment in patients with metastatic NSCLC treated in a nonclinical trial setting. Our findings show that in patients with metastatic NSCLC, the addition of RT to immune checkpoint inhibitors was not associated with increased toxicity or improved survival.
- Abscopal effect
- anti- PD-1 inhibitors
- Immune related adverse events
- Metastatic NSCLC